- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04203992
Videogame for the Prevention of Doping and Supplement Abuse in Teenage Athletes
TRUE CHAMPION: An Educational Videogame Intervention for the Prevention of Doping and Supplement Abuse in Teenage Athletes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lindsay R Duncan, PhD
- Phone Number: 00919 514-398-4184
- Email: lindsay.duncan@mcgill.ca
Study Contact Backup
- Name: Evelyne Bedard, MSc
- Phone Number: 09976 514-398-4814
- Email: evelyne.bedard@mcgill.ca
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject competes in a competitive sport at the high school level or higher
- Able to read and understand English
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Videogame
Educational videogame, five 60-minute sessions over one month
|
True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping. Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way. |
Active Comparator: Booklet
Educational booklet, one session
|
Participants will be given an anti-doping booklet prepared by UNESCO.
This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use of banned substances
Time Frame: 12 months
|
Self-reported use of banned substances for performance enhancement or recovery in sport. This outcome will be measured using a self-reported questionnaire. Scale: Performance-Enhancing Substances and Methods Use Minimum value: 1 - extremely unlikely (better outcome) Maximum value: 7 - extremely likely (worse outcome) |
12 months
|
Use of sport supplements
Time Frame: 12 months
|
Self-reported use of supplements for performance enhancement or recovery in sport. This outcome will be measured using a self-reported questionnaire. Scale: Performance-Enhancing Substances and Methods Use Minimum value: 1 - extremely unlikely (better outcome) Maximum value: 7 - extremely likely (worse outcome) |
12 months
|
Intentions to use banned substances and sport supplements
Time Frame: 12 months
|
Self-reported intentions of using banned substances or supplements for performance enhancement or recovery in sport. This outcome will be measured using a self-reported questionnaire. Scale: Performance-Enhancing Substances and Methods Use Minimum value: 1 - extremely unlikely (better outcome) Maximum value: 7 - extremely likely (worse outcome) |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knowledge
Time Frame: 12 months
|
Knowledge of anti-doping rules, definitions and consequences of doping. This outcome will be assessed using a True/False questionnaire. |
12 months
|
Doping Self-Regulatory Efficacy
Time Frame: 12 months
|
Self-efficacy for refusing doping under a variety of pressure situations. This outcome will be measured using a validated questionnaire. Scale: Doping Self-Regulatory Efficacy Minimum value: 1 - no confidence (better outcome) Maximum value: 5 - complete confidence (worse outcome) |
12 months
|
Motivation
Time Frame: 12 months
|
Motivations for abstaining from doping. This outcome will be measured using an adaptation of a validated questionnaire. Scale: Treatment Self-Regulation Questionnaire for the Avoidance of Doping in Sport Minimum value: 1 - not true at all (worse outcome) Maximum value: 7 - very true (better outcome) |
12 months
|
Attitudes
Time Frame: 12 months
|
Attitudes towards doping in sport. This outcome will be measured using a subscale from a validated questionnaire. Scale: The Adolescent Sport Doping Inventory Minimum value: 1 - strongly disagree (worse outcome) Maximum value: 7 - strongly agree (better outcome) Note: some items are reverse-scored |
12 months
|
Anti-doping protective behaviours
Time Frame: 12 months
|
Self-reported engagement in behaviours linked to doping abstinence. Scale: Microbehaviours Minimum value: 1 - never (worse outcome) Maximum value: 7 - always (better outcome) |
12 months
|
Doping refusal
Time Frame: 12 months
|
Self-report of having refused a supplement or performance-enhancing substance. This outcome will be assessed using a Yes (worse outcome) or No (better outcome) questionnaire. |
12 months
|
Gameplay experience
Time Frame: 1 month
|
Enjoyment and acceptability of the True Champion videogame among players assigned to the intervention condition. This outcome will be assessed using a questionnaire we have created. Answers will range from "strongly disagree" to "strongly agree". |
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lindsay R Duncan, PhD, McGill University
Publications and helpful links
General Publications
- Goulet C, Valois P, Buist A, Cote M. Predictors of the use of performance-enhancing substances by young athletes. Clin J Sport Med. 2010 Jul;20(4):243-8. doi: 10.1097/JSM.0b013e3181e0b935.
- Boardley I, Smith AL, Mills JP, Grix J, Wynne C., & Wilkins L. Development of Moral Disengagement and Self-Regulatory Efficacy Assessments Relevant to Doping in Sport and Exercise. SportRxiv, 12 Oct. 2017. Web.
- Chan DK, Dimmock JA, Donovan RJ, Hardcastle S, Lentillon-Kaestner V, Hagger MS. Self-determined motivation in sport predicts anti-doping motivation and intention: a perspective from the trans-contextual model. J Sci Med Sport. 2015 May;18(3):315-22. doi: 10.1016/j.jsams.2014.04.001. Epub 2014 Apr 13.
- Nicholls AR, Levy AR, Meir R, Sanctuary C, Jones L, Baghurst T, Thompson MA, Perry JL. The development and validation of the Adolescent Sport Drug Inventory (ASDI) among athletes from four continents. Psychol Assess. 2019 Nov;31(11):1279-1293. doi: 10.1037/pas0000750. Epub 2019 Jul 18.
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 476-0418
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Performance Enhancing Product Use
-
Christopher BellRecruiting
-
Walter Reed Army Institute of Research (WRAIR)Enrolling by invitationPerformance Enhancing Product UseUnited States
-
U.S. Army Medical Research and Development CommandWalter Reed Army Institute of Research (WRAIR)Enrolling by invitationSleep | Performance Enhancing Product Use
-
University of ReginaUnknown
-
University Medical Centre LjubljanaCompletedRecovery | Physical Fitness | Sport | Performance Enhancing Product UseSerbia
-
PharmanexUniversity of North Carolina, Chapel HillCompletedBody Weight Changes | Performance Enhancing Product Use | Damage MuscleUnited States
-
MJN Neuroserveis, S.LClinica Universidad de Navarra, Universidad de Navarra; Oxford University Hospitals... and other collaboratorsNot yet recruitingQuality of Life | Performance Enhancing Product Use
-
PharmanexUniversity of North Carolina, Chapel HillCompletedSoreness, Muscle | Performance Enhancing Product Use | Damage MuscleUnited States
-
Long Island UniversityCalifornia State University, Los AngelesCompletedPERFORMANCE-ENHANCING EFFECT
-
Francisco Javier Martínez NogueraCompletedAntioxidative Stress | Lactate Blood Increase | Performance Enhancing Product Use | Change, Body Weight | Change, Body Temperature | Thermal Sensation DisordersSpain
Clinical Trials on Videogame
-
NYU Langone HealthCompleted
-
Yale UniversityDigitalmillCompletedHuman Immunodeficiency Virus
-
Ascentys LtdNot yet recruitingDementia AlzheimersUnited Kingdom
-
Universidad Nacional Autonoma de MexicoEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezRecruiting
-
University of Southern CaliforniaCompleted
-
Yale UniversityCompleted
-
Massachusetts General HospitalHarvard University; American Academy of Child Adolescent Psychiatry.UnknownAnger | AggressionUnited States
-
Bronx VA Medical CenterVISN 3 Mental Illness Research, Education and Clinical CenterCompletedPosttraumatic Stress DisorderUnited States
-
Yale UniversityCompletedSelf Efficacy | Cognitive ReappraisalUnited States